DO. Normal cardiac function in mice with supraphysiological cardiac creatine levels. Am J Physiol Heart Circ Physiol 306: H373-H381, 2014. First published November 22, 2013; doi:10.1152/ajpheart.00411.2013.-Creatine and phosphocreatine levels are decreased in heart failure, and reductions in myocellular phosphocreatine levels predict the severity of the disease and portend adverse outcomes. Previous studies of transgenic mouse models with increased creatine content higher than two times baseline showed the development of heart failure and shortened lifespan. Given phosphocreatine's role in buffering ATP content, we tested the hypothesis whether elevated cardiac creatine content would alter cardiac function under normal physiological conditions. Here, we report the creation of transgenic mice that overexpress the human creatine transporter (CrT) in cardiac muscle under the control of the ␣-myosin heavy chain promoter. Cardiac transgene expression was quantified by qRT-PCR, and human CrT protein expression was documented on Western blots and immunohistochemistry using a specific anti-CrT antibody. High-energy phosphate metabolites and cardiac function were measured in transgenic animals and compared with age-matched, wild-type controls. Adult transgenic animals showed increases of 5.7-and 4.7-fold in the content of creatine and free ADP, respectively. Phosphocreatine and ATP levels were two times as high in young transgenic animals but declined to control levels by the time the animals reached 8 wk of age. Transgenic mice appeared to be healthy and had normal life spans. Cardiac morphometry, conscious echocardiography, and pressure-volume loop studies demonstrated mild hypertrophy but normal function. Based on our characterization of the human CrT protein expression, creatine and phosphocreatine content, and cardiac morphometry and function, these transgenic mice provide an in vivo model for examining the therapeutic value of elevated creatine content for cardiac pathologies. cardiac failure; creatine transporter; energy metabolism; phosphocreatins A HALLMARK OF CARDIAC FAILURE is a marked disturbance of energy metabolism. In this condition, the manner in which ATP is buffered and transferred, via the creatine kinase (CK) system, from the mitochondria to utilization sites, is profoundly altered (26). In the early stages of heart failure, myocardial creatine (Cr) and phosphocreatine (PCr) are reduced by as much as 70%, whereas a slow and progressive ATP loss of up to 30 -40% is observed at the latter stages of the disease (4,28,39,45). Moreover, the PCr-to-ATP ratio decreases, and this decrease is a better predictor of overall and cardiovascular-related mortality than traditional indexes such as ejection fraction or New York Heart Association symptomatology (27). These deficits in high-energy metabolites are accompanied by decreases in the activity and expression levels of the CKs in the myocardium (22, 38). Recent reports elegantly illustrated that increased CK function has a protective effect in murine models of ...